David K. Loomis Sells 1,214 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) CAO David K. Loomis sold 1,214 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.75, for a total value of $20,334.50. Following the sale, the chief accounting officer now owns 18,863 shares of the company’s stock, valued at approximately $315,955.25. This represents a 6.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Arvinas Trading Down 5.7 %

Shares of ARVN stock opened at $16.75 on Tuesday. Arvinas, Inc. has a twelve month low of $16.07 and a twelve month high of $51.51. The stock has a market cap of $1.15 billion, a P/E ratio of -6.05 and a beta of 1.88. The stock has a 50 day moving average of $18.44 and a 200 day moving average of $22.85.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the company posted ($2.53) EPS. On average, research analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arvinas

A number of hedge funds have recently bought and sold shares of ARVN. JPMorgan Chase & Co. raised its stake in shares of Arvinas by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after buying an additional 367,343 shares during the period. Baker BROS. Advisors LP acquired a new stake in Arvinas in the 3rd quarter valued at $9,989,000. SG Americas Securities LLC increased its holdings in Arvinas by 228.8% in the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock worth $622,000 after acquiring an additional 22,564 shares in the last quarter. Wasatch Advisors LP raised its position in Arvinas by 58.3% during the third quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock worth $10,737,000 after acquiring an additional 160,510 shares during the period. Finally, Barclays PLC lifted its holdings in Arvinas by 198.9% during the third quarter. Barclays PLC now owns 121,699 shares of the company’s stock valued at $2,998,000 after purchasing an additional 80,984 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on ARVN shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $82.00 target price (down from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. HC Wainwright restated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a report on Wednesday, December 11th. Oppenheimer lifted their target price on shares of Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Stifel Nicolaus dropped their target price on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, February 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $57.00 price target on shares of Arvinas in a report on Tuesday, February 11th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $60.00.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.